<DOC>
	<DOCNO>NCT00126308</DOCNO>
	<brief_summary>This multi-centre , open-label , 96 week study evaluate safety , tolerability extent duration improvement HIV-1 infected subject antiretroviral induced facial lipoatrophy , randomise 1:1 ratio receive immediate defer deep subcutaneous injection poly-L-lactic acid ( PLA ) . Subjects receive 4 treatment PLA approximately every 2nd week , either trial entry follow delay period 24 week .</brief_summary>
	<brief_title>Facial Lipoatrophy Trial : Immediate Versus Deferred Injections Poly-L-Lactic Acid HIV Facial Lipoatrophy</brief_title>
	<detailed_description>HIV lipodystrophy distress result suboptimal antiretroviral ( ART ) adherence . Physical change may stigmatise subject negative psychological social impact become major concern . To date , proven therapy lipoatrophy , cosmetic intervention facial lipoatrophy study . Poly-L-lactic acid ( PLA ) show safe effective administer injection facial area . Study aim : 1. evaluate extent duration improvement HIV facial lipoatrophy PLA injection ; 2. evaluate impact PLA injection quality life ART adherence subject HIV facial lipoatrophy ; 3. evaluate safety tolerability polylactic acid . 100 HIV-infected ART-experienced subject facial lipoatrophy randomise 1:1 ratio study entry receive either immediate deferred treatment ( delayed 24 week ) treatment PLA . Randomisation stratify age , severity facial lipoatrophy , current ART ( PI non-PI contain thymidine- non-thymidine-containing ) surgeon . The study clinical end point monitor CD4 cell count , viral load adverse event . The study also psychosocial end point monitor quality life .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<criteria>Aged 18 year laboratory evidence HIV1 infection Received combination antiretroviral therapy ( minimum 2 agent ) Antiretroviral regimen stable least 12 week prior entry change plan first 48 week . For subject antiretroviral therapy entry intent commence therapy first 24 week . Moderate severe facial lipoatrophy lipodystrophy one sit Provide write , informed consent . Active AIDSdefining illness include active HIV waste Active herpes labialis acute currently present chronic skin disease ( infection/inflammation ) on/near area treat Currently anticoagulants coagulopathy would preclude safe deep subcutaneous injection Women : pregnant , breastfeed positive pregnancy test willing use adequate contraception childbearing potential Concomitant therapy anabolic steroid ( except testosterone replacement ) , corticosteroid great replacement dos , growth hormone currently available experimental agent improve appetite weight Testosterone replacement le 6 month great replacement dose Subjects discontinue prohibit concomitant agent/s must cease therapy least 30 day prior screen . Prior use facial dermal filling/tissue expansion agent/s Any condition may interfere ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Intervention</keyword>
	<keyword>Poly-L-lactic acid</keyword>
	<keyword>HIV facial lipoatrophy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>